Diopsys, Inc. is a leading provider of non-invasive medical devices that analyze the entire visual pathway for visual and neuro-visual disorders. The company utilizes technology known as electrophysiology – both Visual Evoked Potential (VEP) and pattern Electroretinography (ERG). It is this technology that powers Diopsys, Inc.’s medical devices – the Diopsys® NOVA-VEP and NOVA-ERG product series and the Enfant® Pediatric VEP Vision Testing System. Our patented technology has been demonstrated as an effective tool in providing objective, functional information to the primary care physician, ophthalmologist and optometrist for the most appropriate and timely treatment to prevent vision loss. This technology is used for the detection of subclinical vision disorders and comparative data for decision making when a diagnosis is equivocal/differential and vision testing in children. It also provides data to help isolate the location of visual pathway abnormalities, monitors progression of disease, and gives the physician and patient an objective, alternative testing methods when the patient or other test results have limitations.
The Enfant® and Diopsys® NOVA Vision Testing Systems have US FDA 510k clearance. In addition, Diopsys vision testing systems have been assessed and certified as meeting the requirements of Directive 93/42/EEC and ISO 13485:2003 for the design and manufacture of non-invasive diagnostic vision testing equipment and carry the CE mark allowing sales of its devices in the European Union (EU).
Diopsys, Inc. is a medical instrumentation company dedicated to advances in preventive health care. The company specializes in the development and marketing of easy-to-use, non-invasive, patient-friendly diagnostic testing equipment utilizing electrophysiology. Diopsys understands the needs of the patient, the parent, and the medical community, and the important role of early medical intervention for correctable health problems, which can lead to the improved quality of life.